Wedmont Private Capital Grows Stake in Organon & Co. (NYSE:OGN)

Wedmont Private Capital raised its stake in shares of Organon & Co. (NYSE:OGN - Free Report) by 453.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 100,539 shares of the company's stock after acquiring an additional 82,372 shares during the quarter. Wedmont Private Capital's holdings in Organon & Co. were worth $1,594,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the stock. Prospera Private Wealth LLC purchased a new position in shares of Organon & Co. in the third quarter worth $25,000. William B. Walkup & Associates Inc. acquired a new stake in Organon & Co. during the 2nd quarter worth about $31,000. Abich Financial Wealth Management LLC grew its stake in Organon & Co. by 5,646.3% during the 3rd quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company's stock valued at $45,000 after purchasing an additional 2,315 shares during the last quarter. Trust Co. of Vermont increased its holdings in shares of Organon & Co. by 109.4% in the third quarter. Trust Co. of Vermont now owns 2,626 shares of the company's stock valued at $50,000 after purchasing an additional 1,372 shares during the period. Finally, Headlands Technologies LLC purchased a new position in shares of Organon & Co. in the second quarter worth about $56,000. 77.43% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Evercore ISI upgraded Organon & Co. to a "strong-buy" rating in a research report on Wednesday, September 18th.

Organon & Co. Stock Performance

Shares of OGN stock traded up $0.18 on Tuesday, hitting $15.84. The company had a trading volume of 2,650,674 shares, compared to its average volume of 3,076,144. Organon & Co. has a twelve month low of $13.87 and a twelve month high of $23.10. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The firm has a market cap of $4.08 billion, a P/E ratio of 3.14, a price-to-earnings-growth ratio of 0.81 and a beta of 0.76. The company has a 50-day moving average price of $15.32 and a 200-day moving average price of $18.30.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The company had revenue of $1.58 billion for the quarter, compared to analysts' expectations of $1.56 billion. During the same quarter in the prior year, the business posted $0.78 earnings per share. The firm's revenue was up 4.1% compared to the same quarter last year. As a group, equities research analysts predict that Organon & Co. will post 3.89 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Tuesday, November 12th were given a dividend of $0.28 per share. The ex-dividend date of this dividend was Tuesday, November 12th. This represents a $1.12 annualized dividend and a yield of 7.07%. Organon & Co.'s dividend payout ratio is presently 22.22%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.